INFLUENCE OF CIRCADIAN TIME OF HYPERTENSION TREATMENT ON CARDIOVASCULAR RISK: RESULTS OF THE MAPEC STUDY

REFERENCES

• Boggia J, Li Y, Thijs L, Hansen TW, Kikuya M, Björklund-Bodegård K, Richart T, Ohkubo T, Kuznetsova T, Torp-Pedersen CH, Lind L, Ibsen H, Imai Y, Wang J, Sandoya E, O'Brien E, Staessen JA. (2007). Prognostic accuracy of day versus night ambulatory blood pressure: a cohort study. Lancet 370:1219–1229.
   PubMed Web of Science ®Google Scholar
• Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, Ferdinand K, Giles TD, Falkner B, Carey RM. (2008). Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 51:1403–1419.
   PubMed Web of Science ®Google Scholar
• de la Sierra A, Redon J, Banegas JR, Segura J, Parati G, Gorostidi M, de la Cruz JJ, Sobrino J, Llisterri JL, Alonso J, Vinyoles E, Pallarés V, Sarría A, Aranda P, Ruilope LM, Spanish Society of Hypertension Ambulatory Blood Pressure Monitoring Registry Investigators. (2009). Prevalence and factors associated with circadian blood pressure patterns in hypertensive patients. Hypertension 53:466–472.
   PubMed Web of Science ®Google Scholar
• Dolan E, Stanton A, Thijs L, Hinedi K, Atkins N, McClory S, Den Hond E, McCormack P, Staessen JA, O'Brien E. (2005). Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. Hypertension 46:156–161.
   PubMed Web of Science ®Google Scholar
• Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Frauss RM, Savage PJ, Smith SC, Spertus JA, Costa F. (2005). Diagnosis and management of the metabolic syndrome. An American Hearty Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112:2735–2752.
   PubMed Web of Science ®Google Scholar
• Hermida RC. (2007). Ambulatory blood pressure monitoring in the prediction of cardiovascular events and effects of chronotherapy: rationale and design of the MAPEC study. Chronobiol. Int. 24:749–775.
   PubMed Web of Science ®Google Scholar
• Hermida RC, Ayala DE. (2009). Chronotherapy with the angiotensin-converting-enzyme inhibitor ramipril in essential hypertension: improved blood pressure control with bedtime dosing. Hypertension 54:40–46.
   PubMed Web of Science ®Google Scholar
• Hermida RC, Fernández JR, Mojón A, Ayala DE. (2000). Reproducibility of the hyperbaric index as a measure of blood pressure excess. Hypertension 35:118–125.
   PubMed Web of Science ®Google Scholar
• Hermida RC, Mojón A, Fernández JR, Alonso I, Ayala DE. (2002). The tolerance-hyperbaric test: a chronobiologic approach for improved diagnosis of hypertension. Chronobiol. Int. 19:1183–1211.
   PubMed Web of Science ®Google Scholar
• Hermida RC, Calvo C, Ayala DE, Domínguez MJ, Covelo M, Fernández JR, Mojón A, López JE. (2003). Administration-time-dependent effects of valsartan on ambulatory blood pressure in hypertensive subjects. Hypertension 42:283–290.
   PubMed Web of Science ®Google Scholar
• Hermida RC, Fernández JR, Ayala DE, Mojón A, Alonso I, Calvo C. (2004). Circadian time-qualified tolerance intervals for ambulatory blood pressure monitoring in the diagnosis of hypertension. Chronobiol. Int. 21:149–170.
   Web of Science ®Google Scholar
• Hermida RC, Calvo C, Ayala DE, López JE. (2005). Decrease in urinary albumin excretion associated to the normalization of nocturnal blood pressure in hypertensive subjects. Hypertension 46:960–968.
   PubMed Web of Science ®Google Scholar
• Hermida RC, Ayala DE, Portaluppi F. (2007a). Circadian variation of blood pressure: the basis for the chronotherapy of hypertension. Adv. Drug. Deliv. Rev. 59:904–922.
   PubMed Web of Science ®Google Scholar
• Hermida RC, Ayala DE, Calvo C, Portaluppi F, Smolensky MH. (2007b). Chronotherapy of hypertension: administration-time dependent effects of treatment on the circadian pattern of blood pressure. Adv. Drug. Deliv. Rev. 59:923–939.
   PubMed Web of Science ®Google Scholar
• Hermida RC, Ayala DE, Fernández JR, Calvo C. (2007c). Comparison of the efficacy of morning versus evening administration of telmisartan in essential hypertension. Hypertension 50:715–722.
   PubMed Web of Science ®Google Scholar
• Hermida RC, Calvo C, Ayala DE, López JE, Rodríguez M, Chayán L, Mojón A, Fontao MJ, Fernández JR. (2007d). Dose and administration-time-dependent effects of nifedipine GITS on ambulatory blood pressure in hypertensive subjects. Chronobiol. Int. 24:471–493.
   PubMed Web of Science ®Google Scholar
• Hermida RC, Ayala DE, Fernandez JR, Mojón A, Calvo C. (2007e). Influence of measurement duration and frequency on ambulatory blood pressure monitoring. Rev. Esp. Cardiol. 60:131–138.
   PubMed Web of Science ®Google Scholar
• Hermida RC, Ayala DE, Mojón A, Fernández JR. (2008a). Chronotherapy with nifedipine GITS in hypertensive patients: improved efficacy and safety with bedtime dosing. Am. J. Hypertens. 21:948–954.
   PubMed Web of Science ®Google Scholar
• Hermida RC, Ayala DE, Mojón A, Chayán L, Domínguez MJ, Fontao MJ, Soler R, Alonso I, Fernández JR. (2008b). Comparison of the effects on ambulatory blood pressure of awakening versus bedtime administration of torasemide in essential hypertension. Chronobiol. Int. 25:950–970.
   PubMed Web of Science ®Google Scholar
• Hermida RC, Ayala DE, Fernández JR, Calvo C. (2008c). Chronotherapy improves blood pressure control and reverts the nondipper pattern in patients with resistant hypertension. Hypertension 51:69–76.
   PubMed Web of Science ®Google Scholar
• Hermida RC, Ayala DE, Chayán L, Mojón A, Fernández JR. (2009). Administration-time-dependent effects of olmesartan on the ambulatory blood pressure of essential hypertension patients. Chronobiol. Int. 26:61–79.
   PubMed Web of Science ®Google Scholar
• Hermida RC, Ayala DE, Mojón A, Fernández JR. (2010a). Effects of time of antihypertensive treatment on ambulatory blood pressure and clinical characteristics of subjects with resistant hypertension. Am. J. Hypertens. 23:432–439.
   PubMed Web of Science ®Google Scholar
• Hermida RC, Ayala DE, Fontao MJ, Mojón A, Alonso I, Fernández JR. (2010b). Administration-time-dependent effects of spirapril on ambulatory blood pressure in uncomplicated essential hypertension. Chronobiol. Int. 27:560–574.
   PubMed Web of Science ®Google Scholar
• Kaplan ER, Meier P. (1958). Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53:457–481.
   Web of Science ®Google Scholar
• Kario K, Hoshide S, Shimizu M, Yano Y, Eguchi K, Ishikawa J, Ishikawa S, Shimada K. (2010). Effect of dosing time of angiotensin II receptor blockade titrated by self-measured blood pressure recordings on cardiorenal protection in hypertensives: the Japan Morning Surge-Target Organ Protection (J-TOP) study. J. Hypertens. 28:1574–1583.
   PubMed Web of Science ®Google Scholar
• Kikuya M, Ohkubo T, Asayama K, Metoki H, Obara T, Saito S, Hashimoto J, Totsune K, Hoshi H, Satoh H, Imai Y. (2005). Ambulatory blood pressure and 10-year risk of cardiovascular and noncardiovascular mortality. The Ohasama Study. Hypertension 45:240–245.
   PubMed Web of Science ®Google Scholar
• Labrecque G, Beauchamp D. (2003). Rhythms and pharmacokinetics. In Redfern P (ed.). Chronotherapeutics. London: Pharmaceutical Press, pp. 75–110.
   Google Scholar
• Lemmer B. (2000). Cardiovascular chronobiology and chronopharmacology. Importance of timing of dosing. In White WB (ed.). Blood pressure monitoring in cardiovascular medicine and therapeutics. Totowa, NJ: Humana Press, pp. 255–271.
   Google Scholar
• Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D, for the Modification of Diet in Renal Disease Study Group. (1999). A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann. Int. Med. 130:461–470.
   PubMed Web of Science ®Google Scholar
• Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Struijker HAJ, Zanchetti A. (2007). 2007 guidelines for the management of arterial hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens. 25:1105–1187.
   PubMed Web of Science ®Google Scholar
• Mantel N. (1966). Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother. Rep. 50:163–170.
   PubMedGoogle Scholar
• Morgan TO. (2009). Does it matter when drugs are taken? Hypertension 54:23–24.
   PubMed Web of Science ®Google Scholar
• Ohkubo T, Hozawa A, Yamaguchi J, Kikuya M, Ohmori K, Michimata M, Matsubara M, Hashimoto J, Hoshi H, Araki T, Tsuji I, Satoh H, Hisamichi S, Imai Y. (2002). Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24-h blood pressure: the Ohasama study. J. Hypertens. 20:2183–2189.
   PubMed Web of Science ®Google Scholar
• Portaluppi F, Smolensky MH. (2000). Circadian rhythm and environmental determinants of blood pressure regulation in normal and hypertensive conditions. In White WB (ed.). Blood pressure monitoring in cardiovascular medicine and therapeutics. Totowa, NJ: Humana Press, pp. 79–118.
   Google Scholar
• Portaluppi F, Touitou Y. Smolensky MH. (2008). Ethical and methodological standards for laboratory and medical biological rhythm research. Chronobiol. Int. 25:999–1016.
   PubMed Web of Science ®Google Scholar
• Salles GF, Cardoso CR, Muxfeldt ES. (2008). Prognostic influence of office and ambulatory blood pressures in resistant hypertension. Arch. Intern. Med. 168:2340–2346.
   PubMed Web of Science ®Google Scholar
• Smith DH, Neutel JM, Lacourciere Y, Kempthorne-Rawson J. (2003). Prospective, randomized, open-label, blinded-endpoint (PROBE) designed trials yield the same results as double-blind, placebo-controlled trials with respect to ABPM measurements. J. Hypertens. 21:1291–1298.
   PubMed Web of Science ®Google Scholar
• Smolensky MH, Hermida RC, Ayala DE, Tiseo R, Portaluppi F. (2010). Administration-time-dependent effect of blood pressure-lowering medications: basis for the chronotherapy of hypertension. Blood Press. Monit. 15:173–180.
   PubMed Web of Science ®Google Scholar
• Staessen J, Fagard R, Lijnen P, Thijs L, Vaa Hoof R, Amery A. (1991). Ambulatory blood pressure monitoring in clinical trials. J. Hypertens. 9( Suppl 1):s13–s19.
   Web of Science ®Google Scholar
• Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, Bulpitt CJ, de Leeuw PW, Dollery CT, Fletcher AE, Forette F, Leonetti G, Nachev C, ÓBrien ET, Rosenfeld J, Rodicio JL, Tuomilehto J, Zanchetti A. (1997). Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 350:757–764.
   PubMed Web of Science ®Google Scholar
• Staessen JA, Thijs L, Fagard R, ÓBrien ET, Clement D, de Leeuw PW, Mancia G, Nachev C, Palatini P, Parati G, Tuomilehto J, Webster J, for the Systolic Hypertension in Europe (Syst-Eur) trial investigators. (1999). Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. JAMA 282:539–546.
   PubMed Web of Science ®Google Scholar
• Svensson P, de Faire U, Sleight P, Yusuf S, Östergren J. (2001). Comparative effects of ramipril on ambulatory and office blood pressures. A HOPE substudy. Hypertension 38:e28–e32.
   PubMed Web of Science ®Google Scholar
• Tofé S, García B. (2009). 24-Hour and nighttime blood pressures in type 2 diabetic hypertensive patients following morning or evening administration of olmesartan. J. Clin. Hypertens. (Greenwhich) 11:426–431.
   PubMed Web of Science ®Google Scholar
• Verdecchia P, Porcellati C, Schillaci G, Borgioni C, Ciucci A, Battistell M, Guerrieri M, Gatteschi C, Zampi I, Santucci A, Santucci C, Reboldi G. (1994). Ambulatory blood pressure: an independent predictor of prognosis in essential hypertension. Hypertension 24:793–801.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. (2000). Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 342:145–153.
   PubMed Web of Science ®Google Scholar